ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zydus Lifesciences board approved FY2026 standalone net profit of Rs 28,137 million (down from Rs 57,749 million in FY2025), a significant 51% decline. However, consolidated revenues grew to Rs 276,579 million from Rs 235,110 million year-on-year. The board recommended a final dividend of Re. 1 per share (100% on face value of Re. 1), totaling approximately Rs 1,006 million, subject to shareholder approval at the AGM on August 11, 2026. The standalone profit decline was partly due to a one-time impairment of Rs 1,068 million in Zydus VTEC Limited and one-time labour code impact of Rs 601 million. The company operates in the single pharmaceuticals segment with operations spanning India and global markets including the US, Europe, and emerging markets.
The sharp standalone profit decline is a concern for standalone-focused investors, though the dividend payout remains steady at Re. 1 per share. The stock may see pressure due to profit contraction, but investors focused on dividends may find stability in the consistent payout.